Scalper1 News
Shire (SHPG) stock popped nearly 3% Thursday after the specialty drugmaker said the FDA had granted priority review to its dry-eye treatment lifitegrast. Shire said the FDA had set a deadline of Oct. 25 to make a decision on the product, which apparently was sooner than many investors had expected. The phase-three trials for the drug produced mixed results, which some analysts doubted would be sufficient for approval. In December, Leerink analyst Scalper1 News
Scalper1 News